Form 8-K

8-K — CVRx, Inc.

Accession: 0001104659-26-109304

Filed: 2026-09-21

Period: 2026-09-16

CIK: 0001235912

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — tm2625806d1_8k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (tm2625806d1_ex10-1.htm)

EX-99.1 — EXHIBIT 99.1 (tm2625806d1_ex99-1.htm)

GRAPHIC (tm2625806d1_ex10-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2625806d1_8k.htm · Sequence: 1

false

0001235912

2026-09-16

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event

reported): September 16, 2026

CVRx,

Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-40545

41-1983744

(State

or other jurisdiction of

incorporation)

(Commission

File Number)

(I.R.S.

Employer

Identification No.)

9201

West Broadway Avenue, Suite 650

Minneapolis,

MN 55445

(Address of principal executive offices) (Zip

Code)

(763)

416-2840

(Registrant’s telephone number, including

area code)

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see

General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange

on which registered

Common stock,

par value $0.01 per share

CVRX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is

an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company x

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Certain

Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 21, 2026, CVRx, Inc. (the “Company”)

announced that its Board of Directors (the “Board”) appointed John Landry as Chief Financial Officer (“CFO”).

Mr. Landry succeeds Jared Oasheim who, as previously disclosed on June 8, 2026, gave notice of his intention to resign as CFO after his

successor commences in the role. Mr. Landry’s employment will commence on October 12, 2026 to facilitate a smooth transition before

assuming the responsibilities of CFO on the day after the Company files its Form 10-Q for its quarter ending September 30, 2026. A copy

of the press release announcing Mr. Landry’s appointment is filed as Exhibit 99.1 hereto.

Mr. Landry, age 54, currently serves as Chief Financial Officer

of Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat obstructive

sleep apnea, a position he has held since November 2024. Mr. Landry previously served as Senior Vice President, Chief Financial Officer,

and Treasurer of Vapotherm Inc., a developer and manufacturer of advanced respiratory technology, from July 2020 to October 2024, prior

to which he served as Vice President, Chief Financial Officer, Secretary and Treasurer from August 2012 to July 2020. Prior to Vapotherm,

Mr. Landry served as Director of International Marketing at Medtronic, Inc. from 2011 to 2012 following its acquisition in August 2011

of Salient Surgical Technologies, Inc., where Mr. Landry held positions of increasing responsibility from 2004 to 2011. Prior to this,

Mr. Landry held various financial leadership roles at Bottomline Technologies, Hussey Seating Company, and Coopers & Lybrand LLP.

Mr. Landry currently serves on the board of directors of Liberate Medical, Inc. Mr. Landry received a B.S. in Accountancy from Bentley

College. He is a certified public accountant (inactive).

The Compensation Committee of the Board approved the following compensation

for Mr. Landry: (i) an initial annual base salary of $500,000, (ii) a target cash incentive award of 50% of base salary (which will be

pro-rated for fiscal 2026), (iii) initial equity awards consisting 75% of stock options and 25% of restricted stock units (“RSUs”)

that together represent 0.80% of the base total common shares outstanding as of the date his employment commences, applying a 1.5:1 multiple

of options to RSUs, which will have terms consistent with the Company’s current forms of equity awards and will be granted under

the Nasdaq inducement grant exemption, (iv) payment of his forfeited pro-rated bonus from his current employer that is subject to repayment

if Mr. Landry resigns or is terminated for cause prior to the first anniversary of his hire date, and (v) reimbursement of travel expenses

from his residence. Mr. Landry will receive the Company’s standard form of severance agreement for executive officers. The foregoing

description of the compensation arrangements is qualified in its entirety by reference to the offer letter, which is filed as Exhibit

10.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements

and Exhibits.

(d) Exhibits

Exhibit

No.

Description

10.1

Offer

letter for John Landry, dated September 16, 2026

99.1

Press

release of CVRx, Inc., dated September 21, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

CVRx, Inc.

Date: September 21, 2026

By:

/s/

Jared Oasheim

Name: Jared Oasheim

Its: Chief Financial Officer

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: tm2625806d1_ex10-1.htm · Sequence: 2

Exhibit 10.1

September 16, 2026

John Landry

10 Days Landing

Biddeford, ME 04005

Dear John,

On behalf of CVRx, Inc. (“CVRx” or the “Company”), I

am pleased to offer you employment with CVRx. Subject to fulfillment of the conditions of employment mentioned in this letter, your estimated

hire date will be October 12, 2026, pending successful completion of enclosed policy acknowledgements and pre-employment screening

described below.

Commencing the day following the Company’s filing of its Form 10-Q

for the quarter ending September 30, 2026, you will transition to the full-time role of Chief Financial Officer reporting to Kevin

Hykes, Chief Executive Officer, and serving as an “executive officer” of the Company. This filing is expected to occur in

early November 2026. In your capacity as Chief Financial Officer, you will serve as the Company’s principal financial officer

and an officer for purposes of Section 16 of the Securities Exchange Act of 1934, and you will also serve as the Company’s

principal accounting officer, treasurer and such other positions as the Company may reasonably request from time to time. During your

employment prior to becoming Chief Financial Officer, you will serve as CFO Designate.

You will be paid an initial annual base salary of $500,000 per year,

to be paid semi-monthly, in two equal installments per month. All compensation will be paid net of all applicable Federal and state income

tax withholding requirements and in accordance with the Company’s current payroll policies. Upon termination of your employment,

you will forfeit all compensation not yet earned as of the date of your termination.

In addition to your base salary, you will be eligible to participate

in the Company's annual Corporate Bonus Plan (CBP) with an initial target potential of 50% of your base salary, which shall be prorated

during your initial year of employment based on your hire date. Plan payouts are expected to be made to qualifying employees on a lump

sum basis (less applicable taxes and withholdings) on or before March 15th following the applicable CBP year. You must be an active

employee at the date of CBP payout to be eligible to receive a bonus.

As a full-time employee, you will be eligible to participate in the

Company’s comprehensive employee benefit program starting the 1st of the month following your start date. Currently

offered benefits include medical, dental, vision, prepaid legal and identity theft insurance, life insurance, short-term disability,

and long-term disability. Other benefits include the CVRx retirement plan, our Flex PTO plan, and 12 Company paid holidays per year (see

benefits link for more information).

9201 West Broadway Ave., #650

Minneapolis, MN 55455 T 763-416-2840 W CVRx.com

Your employment will be based at your home in Maine. When working

in Maine, you will perform your duties from your residence, subject to travel to the Company's offices and other locations as reasonably

necessary to fulfill your duties and responsibilities. When you travel to the Company’s offices or other locations on Company business,

the Company will reimburse you for all reasonable and documented travel expenses you incur in connection with travel between your residence

and the Company's headquarters or required locations, including without limitation airfare, ground transportation, lodging, and meals,

in accordance with the Company's expense reimbursement policies as in effect from time to time, and subject to your submission of reasonable

documentation substantiating such expenses. If the Company determines you are unable to satisfactorily perform your job responsibilities

remotely, the Company may require substantially full-time presence in the Company’s office, which shall not constitute the Company

requiring you to relocate your primary residence.

You will also be eligible to receive a one-time cash payment based

on a reasonable estimate of your forfeited annual cash incentive that you would have received from your current employer for fiscal 2026,

based on actual results under the incentive program and pro-rated for your period of employment with your current employer during fiscal

2026 (less applicable taxes and withholdings), conditioned on you remaining employed by the Company for at least one year following your

start date. This payment will be advanced to you within 30 days following you providing confirmation to the Company of the percentage

of target that was earned by similarly situated executives at your current employer. If your employment ends prior to the one-year anniversary

of your start date, you acknowledge and agree you are not eligible to retain this cash payment and will be required to repay the amount

advanced to you. In this circumstance, you hereby authorize the Company to deduct any portion of the cash payment advanced to you from

your final paycheck(s) to the fullest extent permitted under applicable law.

The Compensation Committee has approved the grant to you of equity

incentive awards in the form of a stock option to purchase shares of the Company’s common stock (the “Stock Option”)

and a restricted stock unit grant for shares of the Company’s common stock (the “RSU”), which together will represent

0.80% of the basic total common shares outstanding as of the date your employment commences, applying a 1.5:1 multiple for Stock Options

versus RSUs. The vesting start date will be the date your employment commences. The grant date will be the date your employment commences

unless the trading window under the Company’s insider trading policy is closed on such date (which is expected to be the case),

in which case the grant date will be the first day on which the trading window opens thereafter, and the exercise price of your Stock

Option will be the closing price of CVRx’s stock on the grant date. The Stock Option and RSU awards will be granted under Nasdaq’s

inducement grant exemption, and will be subject to the same terms and conditions set forth in the Company’s equity incentive plan

and your Stock Option and RSU award agreements.

Following acceptance of this offer and throughout your employment

with CVRx, you must comply with all reasonable Company rules and policies, which you must acknowledge through the enclosed policy

acknowledgments in connection with the commencement of your employment. You will be entitled to prompt reimbursement for approved business

expenses incurred by you in the discharge of your job responsibilities, pursuant to the Company’s standard policy. You should note

that the Company may modify its employment policies, salaries, and/or benefits from time to time as it deems necessary.

9201 West Broadway Ave., #650

Minneapolis, MN 55455 T 763-416-2840 W CVRx.com

As a condition of employment with the Company, you will be expected

to complete the following on or prior to your first day of employment:

· Complete,

sign, and comply with the EMPLOYEE PROPRIETARY INFORMATION, NON-COMPETITION & INVENTIONS

ASSIGNMENT AGREEMENT (linked in offer email).

· Complete

and successfully pass any background check as requested or required for your position.

· Complete

and successfully pass any additional pre-employment screening as requested for your position,

including but not limited to, providing information for reference checks and completing (and

the Company obtaining satisfactory results of) drug screens.

· For

purposes of federal immigration law, you will be required to provide to the Company documentary

evidence of your identity and eligibility for employment in the United States on or before

your first day of employment.

This offer is contingent upon the completion of the above policy acknowledgements

and passing required pre-employment screening before commencing employment with CVRx. Your start date may be delayed if any of the above

requirements are not completed in time for you to start on the estimated start date stated in this offer letter.

Certain roles within CVRx require credentialing by healthcare facilities

in which employees will be working. Those healthcare facilities set requirements for our representatives themselves, generally based

on standards and recommendations by the Centers for Disease Control and other government agencies. Therefore, CVRx has implemented various

policies and practices (the “Policies”), including the CVRx COVID-19 Vaccination Policy, which among other things, may require

certain of our employees to receive vaccinations, including the COVID-19 vaccine, to obtain their credentialing to perform their function.

Any employee who is unable to perform their job responsibilities because of their vaccination status, including because they are unable

to obtain credentials for certain healthcare facilities, may be terminated, subject to any requirements of applicable law.

CVRx reserves the right to modify the Policies at any time in its

sole discretion to adapt to changing circumstances and business needs, consistent with its commitment to maintaining a safe and healthy

workplace. If an employee is later required to be vaccinated by the Policies or other practice, the employee must comply with the updated

vaccine requirements or apply for and obtain an accommodation in accordance with the Policies.

You represent and warrant that you are not contractually prohibited

from becoming employed with CVRx, and the performance of any duties for CVRx will not breach or conflict with any non-competition, confidentiality,

or other obligations you have with previous employer(s). You further represent and warrant that you will not make use of or disclose

any confidential or proprietary information, trade secrets, ideas, or materials from others during your employment with CVRx. You also

agree that you will comply with all other obligations to your former employer(s) and will notify the Company if any proposed activities

by you on behalf of the Company will conflict with such obligations.

Your employment with the Company is at-will. As an employee you may

terminate employment at any time and for any reason whatsoever upon notice to the Company. Similarly, the Company may terminate your

employment at any time and for any reason whatsoever, with or without cause and with or without notice. You may be eligible for certain

benefits upon termination of your employment through an individual agreement or policy of the Company. A copy of the Severance Agreement

applicable to your employment is provided with this letter.

9201 West Broadway Ave., #650

Minneapolis, MN 55455 T 763-416-2840 W CVRx.com

This letter and the documents referenced herein set forth our entire

agreement and understanding regarding your employment and supersede any and all other agreements, either oral or in writing, between

the Company and you. No term of this offer, including, without limitation, the “at will” employment provisions set forth

above, may be amended or modified unless it is set forth in writing and signed by an officer of the Company.

CVRx looks forward to your favorable reply and to a productive and

exciting work relationship. Please confirm your acceptance of this employment offer by signing below and completing the EMPLOYEE PROPRIETARY

INFORMATION, NON-COMPETITION & INVENTIONS ASSIGNMENT AGREEMENT linked in your email offer.

Please feel free to contact me at khykes@cvrx.com or Greg Morrison

at gmorrison@cvrx.com if you have any questions.

Sincerely,

/s/ Kevin Hykes

Kevin Hykes

Chief Executive Officer

CVRx | Barostim

Approved and accepted by:

/s/ John Landry

9/16/26

John Landry

Date

9201 West Broadway Ave., #650

Minneapolis, MN 55455 T 763-416-2840 W CVRx.com

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2625806d1_ex99-1.htm · Sequence: 3

Exhibit 99.1

CVRx Appoints John

Landry as Chief Financial Officer

Landry Brings Two Decades of Medtech and Public Company Finance

Experience

MINNEAPOLIS, Sept. 21, 2026 (GLOBE

NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing,

manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced

that John Landry has been appointed Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously announced.

Mr. Landry will join the Company on October 12, 2026, and assume the CFO role on the day after the Company files its Form 10-Q

for the quarter ending September 30, 2026. Mr. Oasheim will remain with the Company for a transition period consistent

with his previously disclosed transition agreement.

"John is exactly the kind of

finance leader we need for this next chapter," said Kevin Hykes, President and CEO of CVRx. "Over the past two decades,

he has played a key role in building and financing high growth medical device companies introducing novel therapies like Barostim.

He is a hands-on operational leader who has significant commercial and capital markets experience, and who is well known within the

investment community. John’s experience driving growth while managing expenses is particularly relevant as we scale Barostim

and reach more heart failure patients.

"I want to thank Jared for

the significant impact he has had at the company since 2015. He led us through our IPO and helped build the financial foundation

we stand on today," Hykes added. "We're grateful for his contributions and wish him success in his next chapter."

Mr. Landry brings more than

two decades of financial leadership experience in the medical device industry. He currently serves as CFO of Nyxoah SA (Euronext

Brussels/Nasdaq: NYXH), where he raised several rounds of capital and drove operational efficiencies to fund the company's U.S. commercial

expansion. Before that, he spent 12 years at Vapotherm, Inc. (formerly NYSE: VAPO), most recently as Senior Vice President and

CFO, where he led the company's IPO and built its finance, investor relations and public company reporting functions from the ground

up. Earlier in his career, Mr. Landry held finance leadership roles at Salient Surgical Technologies (acquired by Medtronic

in 2011), Bottomline Technologies, Hussey Seating Company and Coopers & Lybrand. He holds a B.S. in Accountancy from Bentley

College, is a CPA (inactive) and serves on the board of Liberate Medical, Inc.

"Barostim is changing how physicians

treat heart failure and the positive impact it is having on patients’ lives is what drew me to this role," said John Landry.

"I've spent most of my career in the medical device industry helping to build the infrastructure and operating discipline needed

as companies scale their commercial efforts. I’m excited to join the CVRx team and see a real opportunity to bring that same

operating discipline to support the business as we execute our commercial growth strategy."

About CVRx, Inc.

CVRx is a commercial-stage medical

device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular

diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients

with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the

carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart

failure.

Barostim received the FDA Breakthrough

Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the

EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic

Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner

ICR Healthcare

443-213-0501

ir@cvrx.com

Media Contact:

Emily Meyers

CVRx, Inc.

763-416-2853

emeyers@cvrx.com

GRAPHIC

Filename: tm2625806d1_ex10-1img001.jpg · Sequence: 7

Binary file (2966 bytes)

Download tm2625806d1_ex10-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.3

Cover

Sep. 16, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 16, 2026

Entity File Number

001-40545

Entity Registrant Name

CVRx,

Inc.

Entity Central Index Key

0001235912

Entity Tax Identification Number

41-1983744

Entity Incorporation, State or Country Code

Entity Address, Address Line One

9201

West Broadway Avenue

Entity Address, Address Line Two

Suite 650

Entity Address, City or Town

Minneapolis

Entity Address, State or Province

Entity Address, Postal Zip Code

55445

City Area Code

763

Local Phone Number

416-2840

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock,

par value $0.01 per share

Trading Symbol

CVRX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration